MBX Biosciences, Inc. Interest and Other Income
MBX Biosciences, Inc. (MBX) reported Interest and Other Income of $3.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2026-08-06
- MBX Biosciences, Inc. interest and other income for the quarter ending 2026-06-30 was $3.84M, a 60.23% increase year-over-year.
- MBX Biosciences, Inc. interest and other income for the quarter ending 2026-03-31 was $3.75M, a 41.49% increase year-over-year.
- MBX Biosciences, Inc. interest and other income for the quarter ending 2025-12-31 was $3.73M, a 23.45% increase year-over-year.
- MBX Biosciences, Inc. interest and other income for the quarter ending 2025-09-30 was $2.31M, a 57.01% increase year-over-year.
- MBX Biosciences, Inc. interest and other income for fiscal 2025 was $11.08M, a 76.72% increase from fiscal 2024.
- MBX Biosciences, Inc. interest and other income for fiscal 2024 was $6.27M, a 128.24% increase from fiscal 2023.
- MBX Biosciences, Inc. interest and other income for fiscal 2023 was $2.75M.
| Period end | Interest and Other Income 3 month | Interest and Other Income 6 month | Interest and Other Income 9 month | Interest and Other Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.84M 10-Q · filed 2026-08-06 | $7.58M 10-Q · filed 2026-08-06 | $11.32M derived: sum of 3 quarters · filed 2026-08-06 | $13.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.75M 10-Q · filed 2026-05-07 | $7.48M derived: sum of 2 quarters · filed 2026-05-07 | $9.79M derived: sum of 3 quarters · filed 2026-05-07 | $12.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $6.04M derived: sum of 2 quarters · filed 2026-03-12 | $8.44M derived: sum of 3 quarters · filed 2026-08-06 | $11.08M 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.31M 10-Q · filed 2025-11-06 | $4.70M derived: sum of 2 quarters · filed 2026-08-06 | $7.35M 10-Q · filed 2025-11-06 | $10.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.39M 10-Q · filed 2026-08-06 | $5.04M 10-Q · filed 2026-08-06 | $8.07M derived: sum of 3 quarters · filed 2026-08-06 | $9.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.65M 10-Q · filed 2026-05-07 | $5.67M derived: sum of 2 quarters · filed 2026-05-07 | $7.14M derived: sum of 3 quarters · filed 2026-05-07 | $7.94M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.49M derived: sum of 2 quarters · filed 2026-03-12 | $5.29M derived: sum of 3 quarters · filed 2026-03-12 | $6.27M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.47M 10-Q · filed 2025-11-06 | $2.27M derived: sum of 2 quarters · filed 2025-11-06 | $3.25M 10-Q · filed 2025-11-06 | $4.40M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $801.00K 10-Q · filed 2025-08-07 | $1.78M 10-Q · filed 2025-08-07 | $2.93M derived: sum of 3 quarters · filed 2025-08-07 | $3.71M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $977.00K 10-Q · filed 2025-05-12 | $2.13M derived: sum of 2 quarters · filed 2025-05-12 | $2.91M derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $1.93M derived: sum of 2 quarters · filed 2025-03-17 | $2.75M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $783.00K 10-Q · filed 2024-11-07 | $1.60M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |